Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Galdakao – page 19

445 clinical trials in Galdakao, Spain across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Galdakao at a glance
445
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

445 trials in Galdakao

Open in trial search

Gastric cancer+2

Not yet recruiting

Study of Disitamab Vedotin and Tucatinib for Patients with Advanced Breast Cancer or Gastric Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Neuroblastoma

Not yet recruiting

Study of ABTL0812 with Irinotecan and Temozolomide for Children with Relapsed or Refractory Neuroblastoma and Other Solid Tumors

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years
  • Sponsor:Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron

Dementia Alzheimer's type

Not yet recruiting

Study on BIIB080 for Patients Aged 50-80 with Mild Cognitive Impairment or Mild Alzheimer's Disease Dementia

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:BIIB080
  • Sponsor:Biogen Idec Research Limited

Rheumatoid arthritis

Not yet recruiting

Study of Peresolimab for Adults with Moderate to Severe Rheumatoid Arthritis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Eli Lilly & Co.

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Macular oedema

Not yet recruiting

Study on the Effects of RO7200220 for Patients with Uveitic Macular Edema

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Acute myeloid leukaemia

Not yet recruiting

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Servier Affaires Medicales

Transitional cell carcinoma

Not yet recruiting

Study Comparing Chemotherapy Before or After Surgery for Patients with Upper Tract Urothelial Carcinoma Using Gemcitabine

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:European Uro-Oncology Group Stichting

Systemic lupus erythematosus

Not recruiting

Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

Registered drug
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Sjogren's syndrome

Not recruiting

Efficacy and Safety Evaluation of Dazodalibep in Patients with Moderate-to-Severe Systemic Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

Sjogren's syndrome

Not recruiting

A study to evaluate the safety of dazodalibep in patients with Sjögren's Syndrome over a long period of time

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Amgen Inc.

Other cities in Spain

The busiest research cities in the country

All 203 cities in Spain

Clinical research in Galdakao

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on breast cancer treatments, including trials for HER2-positive and triple-negative variants. Research encompasses innovative therapies for pancreatic adenocarcinoma and colon cancer.

  • Advanced breast cancer therapies
  • Neoadjuvant chemotherapy approaches
  • Metastatic cancer treatments

Multiple trials evaluating novel drug combinations and targeted therapies for improved patient outcomes.

02 Pulmonary Medicine

Comprehensive research into pulmonary fibrosis and respiratory conditions, with studies examining new treatments for COPD and pulmonary embolism management.

  • Interstitial lung diseases
  • Progressive pulmonary conditions
  • Respiratory therapy optimization

Innovative approaches to improve lung function and patient quality of life.

03 Cardiovascular Studies

Investigations into cardiomyopathy prevention and treatment, including trials for acute coronary syndromes and peripheral arterial disease management.

  • Genetic cardiac conditions
  • Vascular disease treatments
  • Antiplatelet therapy optimization

Focus on preventive strategies and improved treatment protocols for heart conditions.

04 Additional Therapeutic Areas

Studies addressing endocrine disorders, including hypothyroidism and its effects. Research on hepatic conditions and smoking cessation therapies.

  • Liver disease management
  • Addiction treatment
  • Hormonal disorders

Diverse therapeutic approaches targeting various medical conditions.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.